VEGFA and metastatic colorectal cancer: The treatment of metastatic colorectal cancer (mCRC) is challenging, often involving chemotherapeutic agents such as fluoropyrimidines, oxaliplatin, and irinotecan, combined with targeted therapies like anti-vascular endothelial growth factor (VEGF) (bevacizumab) and anti-epidermal growth factor receptor agents (cetuximab, panitumumab) [6].